{
    "clinical_study": {
        "@rank": "45077", 
        "arm_group": [
            {
                "arm_group_label": "S1+Docetaxel", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "S1+Docetaxel followed by S1", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Stage 1:First line therapy Sequential therapy of S1+Docetaxel followed by S1 is superior to\n      concomitant S1+Docetaxel in the safety and clinical efficiency.\n\n      Stage 2:Second line therapy To explore the feasibility of single drug(S1) maintenance\n      treatment for advanced gastric cancer."
        }, 
        "brief_title": "Study Comparing Sequential Therapy of S1+Docetaxel Followed by S1 to Concomitant S1+Docetaxel for Advanced Gastric Cancer", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent form\n\n          -  Performance Status-Eastern Cooperative Oncology Group (ECOG) 0-1\n\n          -  Histologically or cytologically confirmed gastric cancer\n\n          -  Advanced or recurrent, metastatic disease\n\n          -  At least have one measurable disease(according to RECIST, Response Evaluation\n             Criteria in Solid Tumors )\n\n          -  Life expectancy of at least 3 months\n\n          -  Target target lesion has not received radiotherapy or non target lesion radiation at\n             least 4 weeks\n\n          -  Haematopoietic and Hepatic status:\n\n        Absolute neutrophil count >1.5x109/L,Platelet count > 100 x 109/L,Hemoglobin at least 9\n        g/dl,Bilirubin \u2264 1.5 x upper limit of normal (ULN),AST and ALT \u2264 2.5 times ULN(no liver\n        metastasis), \u22645 times ULN(with liver metastasis)\n\n          -  Cardiovascular: Baseline LVEF 50% measured by echocardiography\n\n        Exclusion Criteria:\n\n          -  Symptomatic brain metastasis\n\n          -  Active or uncontrolled infection\n\n          -  Unresolved or unstable, serious toxicity from prior cancer treatment (any toxicities\n             greater than grade 2; peripheral neuropathy of grade 2 or greater Symptomatic brain\n             metastasis\n\n          -  Known history of uncontrolled or symptomatic angina, clinically significant\n             arrhythmias, congestive heart failure, uncontrolled hypertension (\u2265 180/110),\n             unstable diabetes mellitus, dyspnea at rest, or chronic therapy with oxygen\n\n          -  History of other malignancy\n\n          -  Pregnant or lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01718626", 
            "org_study_id": "HBTH101"
        }, 
        "intervention": [
            {
                "arm_group_label": "S1+Docetaxel", 
                "description": "Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks, Patients will receive S1+Docetaxel until progression", 
                "intervention_name": "S1+Docetaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "S1+Docetaxel followed by S1", 
                "description": "Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks,for 4 cycles; S1 40-60mg, bid, days1-14, every 3 weeks Patients will receive S1+Docetaxel followed by S1 until progression", 
                "intervention_name": "S1+Docetaxel followed by S1", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Docetaxel"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 5, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shijiazhuang", 
                    "country": "China", 
                    "state": "Hebei", 
                    "zip": "050011"
                }, 
                "name": "Department of Medical Oncology"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Hebei Tumor Hospital", 
            "last_name": "Wei Liu", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival(PFS)", 
            "safety_issue": "Yes", 
            "time_frame": "1 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01718626"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response rate(ORR)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Disease control rate(DCR)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Overall survival(OS)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Hebei Tumor Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hebei Tumor Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}